Back

uniQure reports 44% slowing in Huntington’s disease progression with AMT-130

Verifying
  • uniQure released four-year data from its phase 1/2 AMT-130 trial.
  • AMT-130 showed a 44% slowing in progression at year 4.
  • The cUHDRS result was not statistically significant, according to uniQure.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.